Renske van den Bijgaart and Gosse Adema, theme Cancer development and immune defence received a grant from Villa Joep, entitled “Bifunctional anti-GD2 antibodies co-targeting innate immune checkpoints to improve immunotherapy of Neuroblastoma”.
In this grant the, ROI research team will develop novel bifunctional monoclonal antibody formats that target the GD2 tumor-associated antigen on Neuroblastoma (NBL) and locally activate the immune system.
Renske van den Bijgaart and Gosse Adema both are from the Radiotherapy & OncoImmunology (ROI) laboratory (Department of Radiation Oncology) and in collaboration with the Prinses Maxima Center (Peter Hoogerbrugge) they received this Villa Joep grant of 410K Euro.
Related news items
A single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta21 June 2022
The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription.read more
Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs14 June 2022
The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma.read more
2.5 million Euros for cancer research into ovarian cancer and immunotherapy15 April 2021
The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period.read more